Evidence map›Paper›PMID 41593124›Full record

ArticleScientific reports2026

Exploration of real-world outcomes in patients with previously treated HR+/HER2- and triple negative metastatic breast cancer.

Natalia Sadetsky, Patricia Prince, Helen Latimer, Pooja Advani, Demetria Smith-Gaziani, Peter A Kaufman, Yanina Natanzon, Aliki Taylor, Linda Nguyen, Nick Freemantle

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Natalia SadetskyReal World Evidence Oncology, Gilead, 303 Lakeside Drive, Foster City, CA, 94404, USA. Natalia.Sadetsky@gilead.com.
Patricia PrinceAetion, New York, NY, USA.
Helen LatimerAetion, New York, NY, USA.
Pooja AdvaniMayo Clinic, Jacksonville, FL, USA.
Demetria Smith-GazianiEmory University, Atlanta, GA, USA.
Peter A KaufmanUniversity of Vermont, Burlington, VT, USA.
Yanina NatanzonConcertAI, Cambridge, MA, USA.
Aliki TaylorGilead Sciences Europe,LTD, Uxbridge, UB11 1AF, UK.
Linda NguyenReal World Evidence Oncology, Gilead, 303 Lakeside Drive, Foster City, CA, 94404, USA.
Nick FreemantleUniversity College London, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Curated electronic health records offer valuable insights into real-world outcomes for patients with advanced tumors. We described real-world treatment effectiveness among patients with HR+/HER2- metastatic breast cancer (mBC) and metastatic triple-negative breast cancer (mTNBC) using ConcertAI Patient360™ Breast Cancer dataset. Patients initiating therapies selected based on literature review and data availability in the metastatic setting between January 1, 2016, and November 30, 2021, were included. Real-world response rate (rwRR), progression-free survival (rwPFS), overall survival (rwOS), time-to-next treatment (rwTTNT), and time-to-discontinuation (rwTTD) were assessed. Three HR+/HER2- mBC cohorts included 292 patients treated with palbociclib + fulvestrant, 274 patients treated with fulvestrant monotherapy, and 381 patients treated with paclitaxel-based therapy; the mTNBC cohort included 247 chemotherapy-treated patients. Median rwOS in three HR+/HER2- cohorts ranged from 15.6 to 32.3 months and was 13 months in mTNBC; median rwPFS ranged from 5.6 to 8.6 months, and 4.4 months, respectively. The alignment between several real-world and clinical trial endpoints is encouraging and supports the utility of real-world data in contextualizing outcomes, though interpretation may be influenced by data completeness and variability in clinical documentation. These insights are particularly relevant for populations with persistent unmet clinical needs.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsErb-b2 Receptor Tyrosine KinasesTriple Negative Breast NeoplasmsAdultAgedFemaleFulvestrantHumansMiddle AgedNeoplasm MetastasisPaclitaxelPiperazinesProgression-Free SurvivalPyridinesReceptors, EstrogenReceptors, ProgesteroneERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesFulvestrantPaclitaxelpalbociclibPiperazinesPyridinesReceptors, EstrogenReceptors, ProgesteroneClinical trialsCorrelation coefficientsHR+/HER2-BCMetastatic triple-negative BCOverall survivalProgression-free survivalReal-world dataResponse rateTime to next treatment or death

Identifiers

PMID41593124
PMCPMC12848001

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.